X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/aptar-takes-option-orbital-high-dose-dry-powder-inhaler-pursuit-halcyon-drug-delivery-days
https://www.contractpharma.com/contents/view_breaking-news/2022-08-05/aptar-pharma-acquires-worldwide-rights-to-pharmaxis-orbital-inhaler/?widget=listSection
https://www.prnewswire.com/news-releases/fda-clears-pharmaxis-cancer-drug-to-progress-to-phase-2-study-in-liver-cancer-301419232.html
https://www.prnewswire.com/news-releases/pharmaxis-cleared-to-progress-to-phase-2-bone-marrow-cancer-trial-301392552.html
https://www.prnewswire.com/news-releases/pharmaxis-treatment-to-prevent-wound-and-burns-scars-clears-phase-1-trial-301365745.html
https://www.contractpharma.com/contents/view_breaking-news/2021-08-17/aptar-pharma-pharmaxis-enter-orbital-dpi-agreement/?widget=listSection
https://www.prnewswire.com/news-releases/pharmaxis-cancer-drug-decreases-tumour-burden-in-pre-clinical-liver-cancer-model-301348985.html
https://www.pharmaxis.com.au/assets/Documents/pdf/02021/ASX/2021-07-01-BTC-Agreement.pdf
https://www.proactiveinvestors.com/companies/news/953705/pharmaxis-encouraged-by-first-results-in-bone-marrow-cancer-trial-953705.html
https://www.pharmiweb.com/press-release/2021-06-11/pharmaxis-announces-progression-of-clinical-trial-in-bone-marrow-cancer
Market Place
Share 
